Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

ASCO® 2023 Insights: "Dose Expansion Results of the Bifunctional EGFR/TGFβ Inhibitor BCA101 + Pembro in Pts With Recurrent, mHNSCC"

0 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login